CG
JNCE

Cutler Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Cutler Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-400
Closed -$1K – 4963
2018
Q4 		$1K Hold
400
– – ﹤0.01% 3772
2018
Q3 		$2K Hold
400
– – ﹤0.01% 3634
2018
Q2 		$3K Buy
+400
New +$5.77K ﹤0.01% 3462

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Cutler Group's JNCE Position: Q1 2019 in Review

Cutler Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2019, closing a stake of 400 shares — an estimated $1K sold.

Cutler Group first reported a position in JNCE in Q2 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

  • Cutler Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Cutler Group sold 400 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $1K.
  • Cutler Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • Cutler Group's Jounce Therapeutics, Inc. Common Stock position peaked at $3K in Q2 2018.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Cutler Group's 13F filing for Q1 2019, filed 10 May 2019.